Clinical Trial Update: The Impact of Deferasirox on Non-Alcoholic-Steatohepatitis [Phase 1, Phase 2]

View source ↗

Summary

A Phase 1/2 trial evaluating the iron chelator deferasirox in non-alcoholic steatohepatitis with abnormal iron storage, which has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-alcoholic Steatohepatitis

Drugs mentioned

• Deferasirox (Deferasirox)

Snippet

Sponsor: Crolll Gmbh | Conditions: Non-alcoholic Steatohepatitis, Increased Iron Storage / Disturbed Distribution | Phase 1, Phase 2 | Status: COMPLETED